Atavistik Bio Raises $120 Million Series B Financing to Advance the Development of Selective Allosteric Small Molecule Therapeutics for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and Myeloproliferative Neoplasms (MPNs) Portfolio News / By Libby Nunan Atavistik Bio Raises $120 Million Series B Financing to Advance the Development of Selective Allosteric Small Molecule Therapeutics for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and Myeloproliferative Neoplasms (MPNs) Read More »
Hexagon Bio Forms Joint Venture with Corteva, Powering Next Generation of Nature Inspired Solutions for Crop Protection Portfolio News / By Libby Nunan Hexagon Bio Forms Joint Venture with Corteva, Powering Next Generation of Nature Inspired Solutions for Crop Protection Read More »
Kenai Therapeutics Announces First Patient Dosed in Phase 1 REPLACE™ Clinical Trial of Neuron Replacement Cell Therapy RNDP-001 for Idiopathic Parkinson’s Disease Portfolio News / By Libby Nunan Kenai Therapeutics Announces First Patient Dosed in Phase 1 REPLACE™ Clinical Trial of Neuron Replacement Cell Therapy RNDP-001 for Idiopathic Parkinson’s Disease Read More »
InduPro Therapeutics Announces Strategic Investment from Sanofi and a Research Collaboration to Advance a Novel Bispecific for Autoimmune Disorders Portfolio News / By Libby Nunan InduPro Therapeutics Announces Strategic Investment from Sanofi and a Research Collaboration to Advance a Novel Bispecific for Autoimmune Disorders Read More »
Neurona Therapeutics Presents New Long-Term Clinical Data from NRTX-1001 Cell Therapy Trials at 2025 Annual Meeting of the American Epilepsy Society Portfolio News / By Libby Nunan Neurona Therapeutics Presents New Long-Term Clinical Data from NRTX-1001 Cell Therapy Trials at 2025 Annual Meeting of the American Epilepsy Society Read More »
Kallyope Announces Positive Results from Phase 2b Study of Elismetrep for the Acute Treatment of Migraine Portfolio News / By Libby Nunan Kallyope Announces Positive Results from Phase 2b Study of Elismetrep for the Acute Treatment of Migraine Read More »
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025 Portfolio News / By Libby Nunan ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025 Read More »
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025 Portfolio News / By Libby Nunan ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025 Read More »
Atavistik Bio to Present Discovery of JAK2 V617F Mutant-Selective Allosteric Inhibitors for the Treatment of Myeloproliferative Neoplasms (MPNs) at ASH 2025 Portfolio News / By Libby Nunan Atavistik Bio to Present Discovery of JAK2 V617F Mutant-Selective Allosteric Inhibitors for the Treatment of Myeloproliferative Neoplasms (MPNs) at ASH 2025 Read More »
Circle Pharma Appoints Anne E. Borgman, M.D., as Chief Medical Officer Portfolio News / By Libby Nunan Circle Pharma Appoints Anne E. Borgman, M.D., as Chief Medical Officer Read More »
